Topics:

ASA404 lung ca trial expanded

ASA404 lung ca trial expanded

LONDON—Antisoma plc announced that its licensing partner Novartis plans to start a pivotal phase III trial of ASA404 in non-small-cell lung cancer in early 2008. This trial has been expanded to include patients with nonsquamous as well as squamous disease, a change that more than doubles the population of NSCLC patients addressed by the trial.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.